Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (SKU C8688, APExBIO) is a potent, orally bioavailable small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1 with low nanomolar IC₅₀ values (Lin et al., 2018). It suppresses angiogenesis by inhibiting endothelial cell migration and tube formation, outperforming reference TKIs like sunitinib and sorafenib under comparable conditions (Lin et al., 2018). Anlotinib demonstrates favorable pharmacokinetics, high plasma protein binding, and minimal toxicity in preclinical models (APExBIO Product Page). It is used in research to elucidate tyrosine kinase signaling and tumor angiogenesis mechanisms. All data are substantiated with peer-reviewed sources and stable product documentation.

Biological Rationale

Cancer progression relies on tumor angiogenesis, the process of forming new vasculature from pre-existing blood vessels (Lin et al., 2018). Key pro-angiogenic factors—vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and fibroblast growth factor 2 (FGF-2)—activate their respective tyrosine kinase receptors (VEGFR2, PDGFRβ, FGFR1) on endothelial cells, initiating signaling cascades that drive proliferation, migration, and capillary morphogenesis. Inhibiting these pathways is an established anti-cancer strategy (Lin et al., 2018).

Traditional multi-target tyrosine kinase inhibitors (TKIs) like sunitinib, sorafenib, and nintedanib exhibit variable selectivity, often with off-target effects or suboptimal potency against certain kinases. Anlotinib was developed to provide superior, targeted inhibition of these critical angiogenic signaling nodes (APExBIO Product Page).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride binds to the ATP-binding sites of VEGFR2, PDGFRβ, and FGFR1, thereby blocking their autophosphorylation and subsequent activation of downstream signaling, notably the ERK pathway (Lin et al., 2018). The compound exhibits the following in vitro potency (mean ± SD):

• VEGFR2: IC₅₀ = 5.6 ± 1.2 nM
• PDGFRβ: IC₅₀ = 8.7 ± 3.4 nM
• FGFR1: IC₅₀ = 11.7 ± 4.1 nM

By preventing receptor phosphorylation, anlotinib disrupts the VEGF/PDGF-BB/FGF-2-induced signaling needed for endothelial cell migration and tube formation. This results in robust inhibition of angiogenic processes at concentrations correlating with kinase inhibition (Lin et al., 2018).

Downstream, this blockade leads to reduced ERK phosphorylation, a key node in cell proliferation and survival pathways. The anti-angiogenic effect is thus achieved by direct multi-receptor inhibition and signaling suppression.

Evidence & Benchmarks

• Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced migration of EA.hy 926 endothelial cells in a concentration-dependent manner (IC₅₀ < 12 nM for all targets) (Lin et al., 2018).
• Capillary-like tube formation by endothelial cells is suppressed by anlotinib at nanomolar concentrations, outperforming sunitinib, sorafenib, and nintedanib in direct comparison (Lin et al., 2018).
• Rat aortic ring and chicken chorioallantoic membrane (CAM) assays confirm reduced microvessel density and sprouting upon anlotinib treatment in vivo (Lin et al., 2018).
• Oral bioavailability ranges from 28–58% in rats and 41–77% in dogs, with high plasma protein binding (~93% in humans) (APExBIO Product Page).
• Safety studies: Median lethal dose (LD₅₀) is 1735.9 mg/kg (14-day oral, rodent), with no significant organ or genetic toxicity (APExBIO Product Page).

For a scenario-driven summary of assay optimization and selectivity in cell-based workflows, see Harnessing Anlotinib (hydrochloride)—this article provides mechanistic updates and quantitative benchmarks beyond its application focus.

For mechanistic details on kinase selectivity and translational insights, refer to Anlotinib Hydrochloride: Next-Generation VEGFR2/PDGFRβ/FGFR1 Inhibitor; the current article extends these findings with updated preclinical pharmacokinetic data and practical safety boundaries.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is intended exclusively for research use. Its validated applications include:

• Capillary tube formation assays with human endothelial cells (e.g., EA.hy 926)
• Cell migration and wound healing assays under VEGF/PDGF-BB/FGF-2 stimulation
• In vivo angiogenesis models (e.g., CAM, aortic ring)
• Assessment of ERK pathway inhibition in tyrosine kinase signaling studies
• Tumor angiogenesis inhibition workflows in cancer research

Common Pitfalls or Misconceptions

• Anlotinib (hydrochloride) is not intended for clinical, diagnostic, or therapeutic use—its safety and efficacy in humans are not established for these purposes (APExBIO Product Page).
• Not all tumor types or cell lines will respond equally; efficacy correlates with VEGFR2/PDGFRβ/FGFR1 pathway dependence (Lin et al., 2018).
• Inhibition potency may vary with serum, protein, or buffer composition due to high plasma protein binding.
• Potential off-target effects outside the VEGFR2/PDGFRβ/FGFR1 axis are not fully characterized.
• Compound stability requires storage at -20°C; repeated freeze-thaw cycles should be avoided to preserve activity (APExBIO Product Page).

Workflow Integration & Parameters

For research workflows, anlotinib hydrochloride (C8688) from APExBIO is provided as a lyophilized powder, to be reconstituted in DMSO or suitable aqueous buffers. Recommended storage is at -20°C. Standard working concentrations for in vitro assays range from 1 nM to 1 μM, with optimal effects observed at 10–100 nM in endothelial cell migration and tube formation assays (Lin et al., 2018).

Pharmacokinetic studies demonstrate rapid oral absorption, large volume of distribution, and predominant CYP3A-mediated metabolism. Tissue distribution includes high accumulation in lung, liver, kidney, heart, and tumor tissue; blood–brain barrier penetration is confirmed in preclinical studies (APExBIO Product Page).

• For anti-angiogenic screening, pre-incubate endothelial cells with anlotinib for 30–60 minutes before adding angiogenic stimuli.
• For migration assays, include controls with VEGF/PDGF-BB/FGF-2 alone and with reference TKIs for benchmarking.
• Monitor ERK phosphorylation by immunoblotting post-treatment to confirm pathway inhibition.

For a focused review of assay optimization and reproducibility, see Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor, which this article updates with additional pharmacokinetic and toxicity boundaries.

For purchasing and technical documentation, refer to the Anlotinib (hydrochloride) product page (APExBIO).

Conclusion & Outlook

Anlotinib hydrochloride is a potent, selective, and well-characterized multi-target tyrosine kinase inhibitor validated for anti-angiogenic research. Its superior efficacy over established TKIs, coupled with favorable pharmacokinetics and safety in preclinical models, make it an optimal tool for dissecting VEGFR2, PDGFRβ, and FGFR1 signaling in cancer and angiogenesis studies (Lin et al., 2018). As a research reagent, it supports reproducible results in cell-based and animal models when used under recommended parameters. Researchers should consult the product documentation and peer-reviewed literature for further protocol guidance. APExBIO provides the C8688 kit for exclusive scientific research use.